LLY. FDA approves updated prescribing information for Tradjenta® (linagliptin) tablets for add-on therapy to insulin in adults with type 2 diabetes
Updated label also includes data on adult patients with type 2 diabetes who have severe chronic renal impairment, providing further evidence TRADJENTA is an efficacious DPP-4 inhibitor with a demonstrated safety profile
http://finance.yahoo.com/news/fda-approves-updated-prescribing-information-185200943.html
Updated label also includes data on adult patients with type 2 diabetes who have severe chronic renal impairment, providing further evidence TRADJENTA is an efficacious DPP-4 inhibitor with a demonstrated safety profile
http://finance.yahoo.com/news/fda-approves-updated-prescribing-information-185200943.html
5-Bagger contest on "Dawgg".
http://bit.ly/qthbYc
Sleepers!
http://bit.ly/Lbsa79
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
